Portrazza (necitumumab; Lillly Oncology) is now available through an exclusive specialty pharmacy provider Biologics, Inc. Eli Lilly announced that physicians and healthcare practices will be able to order Portrazza through Biologics’ specialty pharmacy as an alternative to accessing it via specialty distribution.
Portrazza was approved in November 2015 in combination with gemcitabine and cisplatin for the first-line treatment of patients with metastatic squamous non-small cell lung cancer. It is a a monoclonal antibody that antagonizes epidermal growth factor receptor (EGFR) activity, and is intended for intravenous use.
Portrazza is available as a 800mg/50mL (16mg/mL) strength preservative-free solution in single-dose vials.
For more information call (800) 545-5979 or visit Portrazza.com.